Philadelphia biotech signs exclusive licensing deal with UMBC for cancer treatment candidate

BriaCell Therapeutics Corp., a clinical-stage biotechnology company with operations in Philadelphia and Vancouver, said it has obtained an exclusive license for a potential gene therapy from the University of Maryland, Baltimore County. The new drug candidate, Soluble CD80 (sCD80), is a biologic agent for the treatment of cancer that is designed to restore T cell activation in the immune system. “Our mission has been to develop safe and effective treatments for cancer patients who do not respond…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news